A research group from the ibs.GRANADA leads a European project for the development of a new nanotechnological model of human artificial skin
The Tissue Engineering research group of the Department of Histology of the Faculty of Medicine of the University of Granada, belonging to the Biosanitary Research Institute of Granada (ibs.GRANADA) has developed a new biomaterial based on nanostructured fibrin-agarose hydrogels that has been shown to be effective for the tissue engineering of artificial human cornea, oral mucosa, peripheral nerve and skin, among other applications.
This technology is the critical foundation on which the NanoGrowSkin public-private partnership project, funded by the European call EuroNanoMed III which involves four countries of the European Union. This project is coordinated by the Biosanitary Research Institute of Granada (ibs.GRANADA) -FIBAO Foundation and has as partners / collaborators with the Andalusian Initiative in Advanced Therapies, Italian Biochimic Institute, International Sanitas Organization (Praxis-Biopraxis), Université de Technologie Compiegne, NUI Galway and Université de Bordeaux (Inserm), with a total budget of approximately three million euros.
EuroNanoMed III (2016-2021) is an action ERA-Net Cofund on Nanomedicine in the framework of Horizon 2020 and supports multidisciplinary and translational research and innovation projects that cover: Regenerative Medicine, Diagnosis and Directed Administration Systems. Within the framework of this action, national and regional research funding programs come together with the aim of creating and funding collaborative research and innovation projects that can turn nanotechnology research into practical gains in medicine.
It is a proposal multidisciplinary of tissue engineering and nanotechnology aimed at an improvement in existing therapies for the treatment of chronic wounds, with an emphasis on the development of new advanced therapies of skin regeneration for the treatment of large burns.
The first objective of the project NanoGrowSkin is the optimization of human artificial skin models by using nanoparticles as well as its proof of concept through trials vitro e in vivo. This will allow the generation of artificial tissues with improved biomechanical and antimicrobial properties suitable for therapeutic use. To achieve this first objective, quality controls will be carried out histological, rheological and genetic.
Subsequently, production will be adapted of these new tools towards an optimal regulatory framework, which includes the regulation GMP and the guidelines EMA. For that, NanoGrowSkin has envisaged a broader operating model. It will include the development of a market access to estimate the benefits of this treatment for the entire society. The planned model will include the estimated calculation of the cost per patientas well as potential cost savings and / or cost-effective measures for the affordable introduction of tissue-engineered treatment into healthcare practice.
This project has been funded by AES 2017 of the ISCIII within the framework of the EURONANOMED call.
Award no. AC17 / 00013 by ISCIII thorough AES 2017 and within the Euronanomed framework.